Your new post is loading...
Watchdogs expressed concern that Pfizer and BioNTech's recent vaccine supply deal with the U.S. could lead to price gouging on the final shot. The U.K. pumped $127 million into its vaccine manufacturing capacity, plus the EMA formed a multi-pronged COVID-19 research initiative. And the NIH will launch a suite of large-scale coronavirus therapeutics trials.
With a new U.S. vaccine supply deal under their belts, Pfizer and BioNTech are taking heat from some watchdogs concerned that the partners' shot is overpriced—and worried by Pfizer's refusal to promise a no-profit vaccine. China's Sinopharm said its shot could release to the public before year's end; plus, the U.K. poured nearly $127 million into manufacturing "for any successful" COVID vaccine, approval pending. Meanwhile, the National Institutes of Health is gearing up to launch a "flurry" of large-scale COVID-19 therapeutics trials, and the European Medicines Agency established a new coronavirus research initiative.
Pfizer and BioNTech's $1.95 billion deal to supply 100 million vaccine doses to the U.S. drew ire from watchdogs, who warned that the move could lead to price-gouging later. The agreement includes an option for 500 million more doses at an as-yet-undetermined price. AstraZeneca and Johnson & Johnson both pledged to sell vaccines at no profit to the U.S.—which has shelled out funding for development in both cases—while Pfizer has expressed interest in making at least a marginal return on its shot.....
